Medtronic PLC $MDT Shares Bought by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 20.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 29,386 shares of the medical technology company’s stock after purchasing an additional 5,008 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Medtronic were worth $2,799,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in MDT. Vanguard Group Inc. increased its position in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after buying an additional 1,895,165 shares during the period. Geode Capital Management LLC grew its position in shares of Medtronic by 1.1% during the second quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after acquiring an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Medtronic by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock worth $1,854,616,000 after acquiring an additional 595,549 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after acquiring an additional 98,220 shares during the period. Finally, Invesco Ltd. lifted its position in Medtronic by 3.9% in the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock valued at $1,538,302,000 after purchasing an additional 666,557 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on MDT. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Leerink Partners set a $120.00 price objective on Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. raised their target price on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Royal Bank Of Canada lifted their target price on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Finally, Sanford C. Bernstein boosted their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Fourteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Stock Down 0.4%

Shares of MDT stock opened at $100.98 on Monday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The business’s fifty day moving average is $99.44 and its 200-day moving average is $95.32. The stock has a market cap of $129.45 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s payout ratio is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).